Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Nucleoside compound and application thereof in treatment of feline infectious peritonitis

A compound and drug technology, applied in the field of nucleoside compounds, can solve the problems of large side effects and inability to reduce the high fatality rate of the disease

Pending Publication Date: 2021-07-30
SUZHOU VIGONVITA LIFE SCIENCES CO LTD
View PDF5 Cites 21 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] At present, the treatment of feline infectious peritonitis mainly uses immunomodulators, immunosuppressants and antiviral drugs for symptomatic treatment. These drugs have relatively large side effects and cannot reduce the high fatality rate of the disease

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Nucleoside compound and application thereof in treatment of feline infectious peritonitis
  • Nucleoside compound and application thereof in treatment of feline infectious peritonitis
  • Nucleoside compound and application thereof in treatment of feline infectious peritonitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0054] Embodiment 1: the preparation of compound 32:

[0055]

[0056] Step 1: Add 1.32 g of tert-butoxyacetic acid and 0.84 g of sodium bicarbonate to 30 mL of DMSO, and stir at room temperature for 20 min until dissolved. Add 2.0 g of raw material A1 at room temperature, raise the temperature to 65°C and react overnight, the raw material disappears and the product is formed. The reaction was stopped, extracted with EA / water until the aqueous layer was almost free of products, the organic phase was washed with saturated brine, dried, concentrated and put on the column, eluted with DCM / MeOH=30 / 1 to obtain 1.1 g of white solid B1.

[0057] 1 H NMR (400MHz, DMSO-d 6 )δ8.05–7.86(m,3H),6.92(d,J=4.4Hz,1H),6.82(d,J=4.4Hz,1H),6.36(d,J=6.0Hz,1H),5.42( d,J=5.8Hz,1H),4.68(t,J=5.4Hz,1H),4.38(d,J=9.8Hz,1H),4.28–4.14(m,2H),4.00(s,2H), 3.96–3.89(m,1H),1.12(s,9H).

[0058]Step 2: Dissolve 500 mg of raw compound B1 in 10 mL of DCM, add 3 mL of TFA dropwise under ice-cooling, and react...

Embodiment 2

[0069] Embodiment 2: solubility test

[0070] Experimental method: Determination with reference to high performance liquid chromatography (Chinese Pharmacopoeia 2020 Edition Sibu General Rules 0512).

[0071] a. Take about 1-2mg of the compound, put it in a 10ml measuring bottle, add 1ml of water, shake vigorously for 30 seconds every 5 minutes, and observe for 30 minutes. The test solution.

[0072] b. Take another appropriate amount of the reference substance, dissolve it in a solvent (DMSO: methanol = 10:90) and quantitatively dilute it to make a solution containing 0.1 mg per 1 ml, as the reference substance solution.

[0073] c. Precisely measure 20 μl each of the reference substance and the test solution, inject them into the liquid chromatograph respectively, and calculate the peak area according to the external standard method. The obtained data are shown in Table 2. Calculation formula: In the formula: A 供 : the main peak area of ​​the test solution; A 对 : main ...

Embodiment 3

[0080] Embodiment 3: the drug effect experiment of the feline infectious peritonitis of compound 1,32,85

[0081] experimental method:

[0082] 15 mg of Compounds 1, 32, and 85 were respectively dissolved in 5 mL of solution (water:propylene glycol:PEG=2:1:1) to prepare injection solutions for injection administration. The injection can be stored at room temperature, use a 2mL disposable veterinary syringe to draw the corresponding volume of the injection solution, and remove the air upward. When injecting, choose a site with soft skin, loose subcutaneous tissue and fewer blood vessels, such as the neck or the medial thigh for subcutaneous injection. The dosage is 2 mg / Kg body weight once a day, blood is collected every three days and the blood routine and corresponding biochemical indicators are measured. The biochemical indicators of the cat return to normal as the end of the experiment. The index data measured in the experiment are body weight data and white blood cell dat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a nucleoside compound and application of the nucleoside compound in treatment of feline infectious peritonitis. The compound belongs to a GS-441524 analogue. The compound has a very small toxic effect on normal cells of cats, and has an obvious inhibition effect on feline coronavirus. The compound can be used for preparing a feline coronavirus inhibitor, is used for treating feline infectious peritonitis, has the advantages of good curative effect, high safety and the like, and is very good in water solubility and easier to absorb.

Description

technical field [0001] The invention relates to a nucleoside compound and its application in treating feline infectious peritonitis. Background technique [0002] Feline infectious peritonitis (Feline infectious peritonitis, FIP) is a disease caused by infection with feline coronavirus. It is a chronic, progressive and fatal infectious disease. The disease is clinically common in two forms. One is peritonitis , Exudative type characterized by a large amount of ascites, that is, wet infectious peritonitis. One is dry infectious peritonitis characterized by uveitis such as obvious fibrin clots and retinal hemorrhages in the eyes without obvious symptom changes in the whole body. [0003] At present, immunomodulators, immunosuppressants and antiviral drugs are mainly used in the treatment of feline infectious peritonitis. These drugs have relatively large side effects and cannot reduce the high fatality rate of the disease. Therefore, it is urgent to develop highly effective ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07D487/04A61K31/53A61K31/5377A61P31/14A61P29/00
CPCC07D487/04A61P31/14A61P29/00C07B2200/07
Inventor 雷洋曹刚胡榕
Owner SUZHOU VIGONVITA LIFE SCIENCES CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com